DTB podcast
Summary: From June 2023, all our podcasts will move to https://dtbbmj.podbean.com. You can continue with your subscription on your favourite podcast App. For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
- Visit Website
- RSS
- Artist: BMJ Group
- Copyright: 643134
Podcasts:
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:Tamiflu − the wrong message? DTB 2009; 47: 97Self-monitoring for patients on warfarin? DTB 2009; 47: 98 - 101Non-drug management of chronic low back pain DTB 2009; 47: 102 - 108Correction: How to misinform patients DTB 2009; 47: 108
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:How to misinform patients DTB 2009; 47: 85Management of carpal tunnel syndrome DTB 2009; 47: 86 - 89So, what exactly is a cytokine? DTB 2009; 47: 89 - 91Ezetimibe – an update DTB 2009; 47: 91 - 95Understanding statistical terms: 5 – systematic reviews and meta-analyses DTB 2009; 47: 95 - 96
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:How to misinform patients DTB 2009; 47: 85Management of carpal tunnel syndrome DTB 2009; 47: 86 - 89So, what exactly is a cytokine? DTB 2009; 47: 89 - 91Ezetimibe – an update DTB 2009; 47: 91 - 95Understanding statistical terms: 5 – systematic reviews and meta-analyses DTB 2009; 47: 95 - 96
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:Only in England DTB 2009; 47: 73Melatonin for primary insomnia? DTB 2009; 47: 74 - 77Which approach for first trimester miscarriage? DTB 2009; 47: 77 - 80What are excipients doing in medicinal products? DTB 2009; 47: 81 - 84
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:Only in England DTB 2009; 47: 73Melatonin for primary insomnia? DTB 2009; 47: 74 - 77Which approach for first trimester miscarriage? DTB 2009; 47: 77 - 80What are excipients doing in medicinal products? DTB 2009; 47: 81 - 84
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:Real costs of end-of-life drugs DTB 2009; 47: 61Management of benign paroxysmal positional vertigo DTB 2009; 47: 62 - 66Interferon-gamma release assays and TB diagnosis DTB 2009; 47: 67 - 70Understanding statistical terms: 4 – Diagnostic tests DTB 2009; 47: 71 - 72
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:Real costs of end-of-life drugs DTB 2009; 47: 61Management of benign paroxysmal positional vertigo DTB 2009; 47: 62 - 66Interferon-gamma release assays and TB diagnosis DTB 2009; 47: 67 - 70Understanding statistical terms: 4 – Diagnostic tests DTB 2009; 47: 71 - 72
In January 2009, NICE began a policy for valuing the use of drugs for extending life in people with a short life-expectancy. This development arose from concerns that NICE had been denying patients life-extending treatments because they were too expensive. However, the new policy also raises important ethical and moral dilemmas. In this podcast Dr Martin Duerden, General Practitioner and member of the DTB editorial board, and Dr Ike Iheanacho, DTB Editor, discuss this policy and the issues it raises. This is an extension of our June 2009 Editorial, Real costs of end-of-life drugs DTB 2009; 47: 61.
In January 2009, NICE began a policy for valuing the use of drugs for extending life in people with a short life-expectancy. This development arose from concerns that NICE had been denying patients life-extending treatments because they were too expensive. However, the new policy also raises important ethical and moral dilemmas. In this podcast Dr Martin Duerden, General Practitioner and member of the DTB editorial board, and Dr Ike Iheanacho, DTB Editor, discuss this policy and the issues it raises. This is an extension of our June 2009 Editorial, Real costs of end-of-life drugs DTB 2009; 47: 61.
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:The mad world of epilepsy drugs DTB 2009; 47: 49Update on treatments for head lice DTB 2009; 47: 50 - 52What role for colesevelam in cardiovascular prevention? DTB 2009; 47: 53 - 5Why look at an SPC? DTB 2009; 47: 56 - 58Understanding statistical terms: 3 DTB 2009; 47: 59 - 60
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:The mad world of epilepsy drugs DTB 2009; 47: 49Update on treatments for head lice DTB 2009; 47: 50 - 52What role for colesevelam in cardiovascular prevention? DTB 2009; 47: 53 - 5Why look at an SPC? DTB 2009; 47: 56 - 58Understanding statistical terms: 3 DTB 2009; 47: 59 - 60
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:What are you on? DTB 2009; 47: 37Preventing recurrent venous thromboembolism. DTB 2009; 47: 38 - 41Drospirenone in HRT? DTB 2009; 47: 41 - 4The licensing of medicines in the UK. DTB 2009; 47: 45 – 48
A monthly audio round-up detailing the contents of the latest issue of DTB.Articles:What are you on? DTB 2009; 47: 37Preventing recurrent venous thromboembolism. DTB 2009; 47: 38 - 41Drospirenone in HRT? DTB 2009; 47: 41 - 4The licensing of medicines in the UK. DTB 2009; 47: 45 – 48
Drugs prescribed and administered solely under specialist care or as part of clinical trials, without being specifically recorded in GPs’ prescribing systems, can have serious consequences for patient safety. Here, in our second podcast, Dr Pawan Randev, general practitioner and primary care cancer lead, and Dr Ike Iheanacho, DTB Editor, discuss these issues. This is an extension of our April 2009 Editorial, What are you on? (DTB 2009; 47: 37).
Drugs prescribed and administered solely under specialist care or as part of clinical trials, without being specifically recorded in GPs’ prescribing systems, can have serious consequences for patient safety. Here, in our second podcast, Dr Pawan Randev, general practitioner and primary care cancer lead, and Dr Ike Iheanacho, DTB Editor, discuss these issues. This is an extension of our April 2009 Editorial, What are you on? (DTB 2009; 47: 37).
